The Venture Codex

Participated · Series A · Aug 2026

Infinimmune uses its Anthrobody platform to screen millions of single memory B cells across hundreds of targets to identify naturally paired human antibodies, then applies its GLIMPSE antibody language models to guide optimisation for potency, specificity, half-life and developability. Its lead programmes are IFX-101, a monoclonal antibody targeting interleukin-22 described as a potential first-in-class candidate, and IFX-201, which targets interleukin-13 as a potential best-in-class option for atopic dermatitis. The company expects first-in-human studies for both programmes to begin in 2027 and is advancing additional antibody programmes derived from its human-first discovery approach. Financially, Infinimmune raised $75 million in a Series A co-led by Regeneron Ventures and Playground Global, and earlier support includes ongoing backing from Playground Global since founding. In March 2026 it entered a multi-target collaboration with Merck that includes up to about $838 million in upfront and potential milestone payments, which the company cites as validation of its platform and a potential commercial route.

Led · Series D · Jun 2026

Peregrine Technologies builds an AI-driven platform that connects police records, 911 logs, permit databases, sensor feeds, and other government data to make an agency’s institutional data searchable and usable in real time without collecting or owning that data. The company emphasizes role-based access controls, full audit trails, and that it does not use facial recognition. Peregrine serves more than 400 agencies and organizations representing roughly 125 million people across North America and expects to be working with close to 1,000 cities by year-end. Management has declined to share revenue figures, but says the customer base has more than doubled over the past year. The founders, CEO Nick Noone and CTO Ben Rudolph, previously held roles at Palantir and humanitarian and global health data organizations. Peregrine plans to use new capital for product development, hiring across engineering and implementation, and international expansion while preparing internal operations to be IPO-ready.

Participated · Series C · Mar 2026

Sage builds a fully integrated care platform that pairs software with AI-powered life-safety hardware to support senior living and skilled nursing operations. Its product suite includes Sage Core, Sage Detect, and Tasking, an EHR-integrated workflow, and the company is rolling out a Hardware-as-a-Service model to remove large upfront capital barriers for operators. Sage reports that Sage-powered communities have seen a $275 increase in NOI per resident per month, a 50% reduction in falls, and faster response times compared to the industry. The HaaS approach makes future upgrades part of an ongoing partnership, aligning Sage’s recurring revenue with long-term support and technology refreshes. Sage plans to use recent equity and debt financing to scale this model and expand deployment across communities, enabling faster transitions from signed agreement to full implementation.

Led · Series A · Jan 2026

Northslope develops and deploys AI application suites that sit on top of Palantir AIP, Foundry, and Gotham, giving enterprises bespoke functionality without the cost or delays of fully custom builds. Created by former Palantir Forward Deployed Engineers, the platform lets organizations such as healthcare providers, aerospace manufacturers, and renewable-energy producers tackle domain-specific problems like early cancer detection, rocket manufacturing, and grid optimization. The company combines an "applied AI" approach with a Forward Deployed Engineering model, embedding closely with customers to tailor solutions while retaining SaaS-like speed and maintainability. In the past year Northslope delivered production outcomes across multiple sectors and expanded revenue nearly 7×, signaling strong early commercial traction. Leadership believes one-size-fits-all enterprise software is obsolete and that AI must amplify each customer’s competitive edge. Looking ahead, the fresh capital will be used to scale the engineering model and broaden the firm’s Palantir-native application catalog. Northslope operates globally with hub offices in New York, London, and Denver.

Led · Seed · Dec 2025

Junevity develops therapeutics that repress disease-driving transcription factors with small-interfering RNA (siRNA), leveraging its RESET platform that combines human disease omics, genetic linkages, and ML/AI to identify novel targets previously considered undruggable. Its lead candidate, JUN_01, aims to reprogram metabolic tissue for type 2 diabetes and obesity, showing reduced blood glucose, improved insulin sensitivity, significant weight loss, and twice-yearly dosing in preclinical studies. First-in-human trials for JUN_01 are planned for the second half of 2026. Founded out of UCSF in 2023, the company is also building a pipeline of siRNA programs in neurodegeneration and other complex diseases. Junevity’s long-term vision is to extend lifespan and healthspan by applying siRNA reprogramming across major tissues. To date, the company has secured $20 million in Seed funding, providing runway to complete IND-enabling work and launch initial clinical trials. No commercial revenue has yet been generated, as all programs remain preclinical.